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Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-
driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M
EGFR mutation. To overcome this problem, we analysed the metabonomic differences between two independent pairs of
erlotinib-sensitive/resistant cells and discovered that glutathione (GSH) levels were signiﬁcantly reduced in T790M EGFR
cells. We also found that increasing GSH levels in erlotinib-resistant cells re-sensitised them, whereas reducing GSH levels in
erlotinib-sensitive cells made them resistant. Decreased transcription of the GSH-synthesising enzymes (GCLC and GSS)
due to the inhibition of NRF2 was responsible for low GSH levels in resistant cells that was directly linked to the T790M
mutation. T790M EGFR clinical samples also showed decreased expression of these key enzymes; increasing intra-tumoural
GSH levels with a small-molecule GST inhibitor re-sensitised resistant tumours to erlotinib in mice. Thus, we identiﬁed a new
resistance pathway controlled by EGFR T790M and a therapeutic strategy to tackle this problem in the clinic.
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Introduction
Lung cancer is the main cancer killer and non-small
cell lung cancer (NSCLC) represents ~ 85% of such
cases. About 10% and 30% of NSCLCs in Western and
Asian populations, respectively, express an activated
mutant epidermal growth factor receptor (EGFRm)
and the vast majority (90%) of such patients
respond to ATP-competitive EGFR tyrosine kinase
inhibitors (TKIs) such as geﬁtinib or erlotinib [1–3].
Unfortunately, most patients can quickly acquire TKI
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resistance limiting the beneﬁts of these drugs to
patients' survival.
Resistance mechanisms include Met ampliﬁcation
(~5% of cases) [4] and more frequently (50% of cases) an
additional T790M gatekeeper mutation within the
EGFRm [5–8]. The latter enhances kinase activity by
increasing the afﬁnity of EGFR for ATP, competing out
TKI binding [9]. This led to the development of com-
pounds irreversibly interacting with EGFRm/T790M,
such as afatinib, 324674 andmore recently AZD9291 and
CO1696 [10–12]. However, thus far clinical trials of afa-
tinib failed to demonstrate improved response in
EGFRm/T790M patients [13], and although initial trials
with the irreversible inhibitor AZD9291 showed great
promises, additional resistance mechanisms to these
inhibitors have already surfaced [14].
Changes in cellular metabolism accompany
tumourigenesis and classical chemoresistance [15–17].
Hence, changes in metabolite concentrations can
speciﬁcally reﬂect the onset of therapy resistance,
providing response/outcome biomarkers and novel
therapeutic strategies to reverse resistance [18, 19].
Both 1H-nuclear magnetic resonance (NMR) and mass
spectrometry are efﬁcient tools to investigate these
metabolic changes [20–23].
Here we used 1H-NMR to compare the metabolic
signatures of paired NSCLC cell lines expressing
EGFRm without (erlotinib sensitive) or with the
additional T790M mutation (erlotinib resistant). We
showed that glutathione (GSH) levels were reduced in
erlotinib-resistant NSCLC cells in a T790M-dependent
manner due to the decreased expression of
GSH-synthesising enzymes. Correcting this defect
re-sensitised resistant cells to erlotinib in vitro and
in vivo. Moreover, ethacrynic acid (EA), a glutathione-
S-transferase inhibitor, reversed erlotinib resistance in
T790M NSCLC cells in vitro and in vivo by increasing
GSH levels. As EA is a clinically used diuretic, it could
be repurposed to reverse T790M-mediated erlotinib
resistance in NSCLC patients. Overall, our work
demonstrated the power of metabonomic screening to
generate novel research hypotheses and discover
unexplored strategies to tackle drug resistance in lung
cancer treatments.
Results
1H-NMR-based metabolic proﬁling reveals decreased
GSH levels in erlotinib-resistant NSCLC cells
Two pairs of cell lines were employed to obtain
generic metabonomic phenotypes for the erlotinib-
sensitive and erlotinib-resistant NSCLC cells. The
ﬁrst pair were the isogenically matched PC9 (erlotinib
sensitive) and PC9ER (erlotinib resistant) cells both
containing ΔE746-A750 EGFRm with an additional
T790M (EGFRm/T790M) mutation in PC9ER cells.
The second pair included the H3255 and genetically
unrelated erlotinib-resistant H1975 cell lines sharing
L858R EGFRm, but with an additional T790M
mutation in the H1975. PC9ER and H1975 cells dis-
played signiﬁcant resistance to erlotinib as compared
with their sensitive counterparts (Supplementary
Figure S1A). This resistance was limited to EGFR
TKIs as PC9ER and PC9 cells were equally sensitive to
conventional chemotherapeutic agents (Supplementary
Figure S1B). It has been suggested that the EGFR
T790M-mediated TKI resistance is due to increased
afﬁnity of the receptor for ATP, which displaces com-
petitive inhibitors such as erlotinib [24]. However, both
PC9ER and H1975 showed signiﬁcant resistance even
to the irreversible EGFR inhibitor 324674 compared
with PC9 and H3255 cells, respectively (Supplementary
Figure S1C). This clearly suggests that other
unidentiﬁed molecular mechanisms also contribute to
T790M-mediated TKI resistance.
To identify these, we comprehensively analysed the
1H-NMR metabonomic proﬁles of our erlotinib-
sensitive and -resistant cells. 1H-NMR analysis of cell
extracts from our cell lines identiﬁed 36 metabolites
(Figure 1a) for which unambiguous assignments were
obtained using various two-dimensional NMR meth-
ods (Supplementary Table S1). Statistical analysis of
the spectral data by orthogonal projections to latent
structures discriminant analysis (OPLS-DA) showed
signiﬁcant metabonomic differences between the
erlotinib-resistant and -sensitive cells (Figure 1b and c).
Changes in 14 metabolites mainly involved in GSH,
amino acids, nucleotides and choline metabolism
(Supplementary Figure S2A–C) correlated with resis-
tance in both cell line pairs (Figure 1d; Supplementary
Table S2). Noticeably, a signiﬁcant drop in the intra-
cellular levels of GSH accompanied erlotinib resistance
(Figure 1d; Supplementary Table S2). Such GSH
decrease observed by NMR was independently con-
ﬁrmed using a colorimetric assay (Figure 1e and f).
This was intriguing, as drug resistance was tradition-
ally associated with increased GSH levels [25, 26].
Nevertheless, GSH covalently binds some
chemotherapeutic drugs leading to their glutathione-
S-transferase-mediated extracellular export and
resistance of cancer cells to these compounds [27, 28].
Hence, the increased export of this metabolite in
complex with erlotinib could account for the lower
GSH levels in these resistant cell lines. 1H-NMR
GSH metabolism and erlotinib resistance
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Figure 1Metabolic characteristics for the erlotinib-resistant and -sensitive cells. (a) Typical 600 MHz 1H-NMR spectra of aqueous
extracts from PC9, PC9ER, H3255 and H1975 cells. The region (δ 5.0–9.5) is vertically expanded four times (4 × ). Data
representative of n = 10. Orthogonal projections to latent structures discriminant analysis (OPLS-DA) score plots (left) and
coefﬁcient plots (right) for 1H-NMR spectra of aqueous cellular extracts from PC9ER and PC9 showing signiﬁcantly differentiated
metabolites (b), H1975 and H3255 (c). Models validated by CV-ANOVA, P = 2.36 × 10− 17 (b) and P = 3.04 × 10− 19 (c). The Q2 is
0.99 for both models. The colour scale for coefﬁcient plots reﬂects the differences in the contribution of metabolite variations
between groups. |r| cutoff value is 0.602 (n = 10, Po0.05). For identiﬁcation of peak numbers, see Supplementary Table S1
and d. (d) Metabolites showed statistically signiﬁcant differences between resistant and sensitive cells in both cell line pairs with
statistically signiﬁcant ‘decreases’ or ‘increases’ detected in the erlotinib-resistant (ER) cells as compared with
erlotinib-sensitive (ES) ones. (e, f) GSH levels in PC9 and PC9ER (e) or H3255 and H1975 (f) cells determined by colorimetric
assay. Data are average± s.e.m. of n = 4. Statistics: Student’s t-test. ***Po0.001. See also Supplementary Figures S1 and S2.
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analysis of the culture medium from our four cell lines
disproved this possibility by showing no difference in
secreted GSH between TKI-resistant and -sensitive
cells (Supplementary Figure S2D). Hence, decreased
intracellular GSH levels in erlotinib-resistant cells are
likely due to the changes in GSH metabolism.
Erlotinib-resistant cells have lower expression of
GSH-synthesising enzymes
We investigated whether erlotinib-resistant cells
differed from their sensitive counterparts in
their GSH-metabolic enzymes expression pattern.
Quantitative PCR analysis revealed lower messenger
RNA (mRNA) levels for GSH-synthesising enzymes
(GCLC, GSS and GSR) in erlotinib-resistant cells
compared with sensitive ones (Figure 2a and b). In
addition, mRNA levels for GCLM, the modulatory
subunit of GCLC, were signiﬁcantly lower in H1975
than in H3255 cells. In contrast, changes in the levels
for GSH-catabolic enzymes (GPX1/2/3, GGT and
GSTpi/m1/zi) varied greatly between cell line pairs
and enzyme subtypes indicating no clear pattern
(Figure 2b). Therefore, a reduction in GSH bio-
synthesis becomes a sound explanation for the
decreased GSH levels in EGFRm/T790M erlotinib-
resistant cells.
Figure 2 Intracellular GSH levels modulate response to erlotinib. (a) Schematics of the GSH metabolic pathway. White boxes,
synthesising enzymes; and grey boxes, catabolic enzymes. (b) Quantitative reverse transcription PCR for GSH pathway enzymes
in PC9, PC9ER, H3255 and H1975 cells. Data are relative mRNAs levels in PC9ER (upper panel) and H1975 (lower panel)
normalised to those in PC9 and H3255 cells, respectively. (c) PC9 and PC9ER cells were transfected with siRNA targeting GSH-
catabolic (grey bars) and synthesising (white bars) enzymes or a non-targeting control (NT) and cell survival to erlotinib (50 nM)
monitored by crystal violet staining. Data for the relative survival to erlotinib are normalised to non-targeting control.
Survival to erlotinib of PC9ER (e) and H1975 (f) cells treated with ethacrynic acid (EA) or PC9 (g) and H3255 (h) cells treated
with buthionine sulphoximine (BSO) was monitored by crystal violet staining. Accompanying changes in GSH levels in PC9ER (d)
and PC9 (i) cells were assessed by colorimetric assay. (e–h) Data are the relative responsiveness to erlotinib normalised to vehicle
(− ; DMSO). (b–i) Data representative of ⩾3 experiments and are average of n =3± s.e.m. Statistics: (e–h) analysis of variance,
(b–d, i) Student’s t-test, *P⩽0.05, **P⩽0.01, ***P⩽0.001. See also Supplementary Figures S3 and S4.
GSH metabolism and erlotinib resistance
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Targeting GSH metabolism modulates the cellular
response to erlotinib
NMR results suggested that lower GSH levels
associated with erlotinib resistance. To strengthen this
link, we employed small interfering RNAs (siRNAs)
for GSH-metabolic enzymes to modulate GSH levels
in our cell lines. Silencing of GSH-catabolic enzymes
(GGT1, GPX1 and GSTpi) increased the response
to erlotinib in both the EGFRm PC9 and
EGFRm/T790M PC9ER and H1975 cells (Figure 2c;
Supplementary Figure S3C). This correlated with
efﬁcient targets’ downregulation and a corresponding
increase in GSH levels (Supplementary Figure S3A and
B). Conversely, silencing GSH-synthesising enzymes
(GCLC, GSS and GSR) lowered cellular GSH levels
(Supplementary Figure S3A and B) and rendered the
sensitive PC9 cells erlotinib-resistant (Figure 2c).
To validate our siRNA data, we used small-
molecule inhibitors targeting the activity of GSH
pathway enzymes. Treatment with EA, a known GST
inhibitor, increased GSH levels in erlotinib-resistant
cells (Figure 2d) causing re-sensitisation of PC9ER and
H1975 cells to erlotinib (Figure 2e and f). Similarly,
GPXs inhibition using mercaptosuccinate increased
intracellular GSH levels (Supplementary Figure S3D)
and the response of H1975 cells to erlotinib
(Supplementary Figure S3E). Conversely, GCLC
inhibition using buthionine sulphoximine in sensitive
cells made them erlotinib resistant (Figure 2g and h),
an effect associated with decreased GSH levels
(Figure 2i). Furthermore, EA was also able to sensitise
PC9ER cells to geﬁtinib by increasing intracellular
GSH (Supplementary Figure S4A–C). Taken together,
these data suggest that manipulating GSH levels
controls the responsiveness of our cell lines to erlotinib.
The NRF2 pathway controls GSH synthesis and
responsiveness to erlotinib
GCLC, GSS and GSR are transcriptional targets of
NFE2-related factor 2 (NRF2) [29–31], a downstream
target of EGFR [32]. We therefore hypothesised that
NRF2 activity might be impaired in EGFRm/T790M
cells. NRF2’s transcriptional activity requires its
nuclear localisation and NRF2 is also degraded
through binding to KEAP1, a process counteracted by
Figure 3 Erlotinib resistance correlates with decreased NRF2
activity. (a, b) Subcellular fractions (a) and total lysates (b) from
PC9, PC9ER, H3255 and H1975 cells were analysed by
SDS-PAGE/western blotting for the indicated proteins. Detection
of lamin and tubulin was used as loading controls for nuclear
fractions and total lysates or cytoplasmic fractions, respectively.
(c–h) PC9 cells transfected with non-targeting (NT), NRF2 or
SQSTM1 siRNAs (c–f) or PC9ER cells transfected with KEAP1 or
NT siRNAs (g, h) were treated with erlotinib and survival
assessed by crystal violet staining (c, e, g). GSH levels were
measured by colorimetric assay (d, f, h). (c–h) Data are average
of n = 4± s.e.m. Statistics: Student’s t-test,*P⩽ 0.05, **P⩽ 0.01,
***P⩽ 0.001. See also Supplementary Figures S5 and S6.
Hongde Li et al.
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competitive interaction of the latter protein with
PALB2 and/or SQSTM1. Analysis of nucleocyto-
plasmic fractions and total lysates from our four cell
lines revealed that NRF2 or KEAP1 localisation/
expression had no differences between PC9 and
PC9ER cells, whereas H3255 cells showed higher level
of nuclear NRF2 than H1975 cells (Figure 3a;
Supplementary Figure S5A). This correlated with
increased KEAP1 expression in H1975 as compared
with H3255 cells (Figure 3a; Supplementary
Figure S5B). Although these results alone may
explain the difference in GSH pathway enzymes
expression between the latter two cell lines, they cannot
account for that seen between PC9 and PC9ER cells.
However, SQSTM1 was downregulated in both
PC9ER and H1975 cells as compared with their
erlotinib-sensitive counterparts (Figure 3b;
Supplementary Figure S5C), whereas PALB2 levels
were lower in PC9ER as compared with PC9 cells
(Figure 3b; Supplementary Figure S5D). Furthermore,
NRF2 has been shown to be a transcriptional regulator
of SQSTM1 and, indeed, mRNA levels of SQSTM1
were found to be signiﬁcantly lower in both the resis-
tant cell line pair (Supplementary Figure S5E and F).
Hence, inhibition of NRF2 activity through various
mechanisms may be linked to erlotinib resistance in
NSCLC cells.
To test this hypothesis, we silenced NRF2, SQSTM1,
PALB2 and KEAP1 in our cells. siRNA-mediated
silencing of NRF2 (Supplementary Figure S6A) ren-
dered PC9 cells erlotinib resistant, a change associated
with lower intracellular GSH (Figure 3c and d).
Indeed, NRF2-silenced cells showed downregulation of
the GSH-synthesising enzymes GCLC and GSR
(Supplementary Figure S6B), demonstrating a direct
link between NRF2 activity and GSH synthesis. Simi-
larly, SQSTM1 silencing (Supplementary Figure S6C
and D) decreased the sensitivity of PC9 cells to erlotinib
(Figure 3e) in association with a drop in GSH levels
(Figure 3f). Conversely, KEAP1 downregulation
(Supplementary Figure S6E) sensitised EGFRm/
T790M PC9ER cells to erlotinib (Figure 3g), accom-
panied by the increased GSH levels (Figure 3h) and
increased transcription of GSH-synthesising enzymes
GCLC, GSR and GSS (Supplementary Figure S6F).
Finally, despite the changes in PALB2 between PC9ER
and PC9 cells (Figure 3b), silencing this protein in PC9
cells failed to induce erlotinib resistance or alter GSH
levels (Supplementary Figure S7A and B). Hence, the
modulation of NRF2 activity through KEAP1 and
SQSTM1 regulates the sensitivity of NSCLC cells to
erlotinib.
Inhibition of NRF2 activity and decreased GSH levels
are direct consequences of the T790M mutation
Although lower GSH levels and NRF2 activity were
associated with T790M-driven erlotinib resistance in
our cell lines, this may still be incidental unless the
T790M mutation directly induces these changes. We
further expressed the active (L858R) or active/resistant
(L858R/T790M) EGFR mutants in HEK293 cells that
contain low endogenous EGFR levels (Figure 4a).
Unlike expression of the L858R-EGFR, expression of
the L858R/T790M double-mutant receptor reduced
intracellular GSH levels (Figure 4b). This was
associated with reduced PALB2 and SQSTM1
expression (Figure 4c). Conversely, transfection with
two independent siRNA sequences previously
shown to selectively target T790M-mutant EGFR [33]-
sensitised PC9ER cells to erlotinib (Figure 4d;
Supplementary Figure S7C and D) and increased GSH
levels (Figure 4e). The latter correlated with a reversal
of changes in the expression pattern of GSH metabolic
enzymes observed between PC9 and PC9ER cells
(Figure 4f vs Figure 2b) and with increased PALB2,
SQSTM1 and NRF2 levels in T790M-silenced cells
(Figure 4g). Therefore, lower GSH levels in T790M
NSCLC cells are a direct consequence of acquiring this
mutation and the accompanying impairment of NRF2
activity.
Decrease in GSH correlates with increased nitric oxide
levels
As GSH buffers reactive oxidative species, we
investigated whether lower GSH levels in erlotinib-
resistant cells associated with elevated reactive
oxidative species. We performed ﬂow cytometry
analysis in the presence of dihydroethidine and DAF-
FM (4-amino-5-methylamino-2′,7′-diﬂuoroﬂuorescein
diacetate) to detect superoxide and nitric oxide (NO)
species, respectively. Erlotinib-resistant cells showed an
increase in NO species (Figure 5a), although they did
not show increased superoxide levels. To assess
whether this could inﬂuence erlotinib resistance, we
ﬁrst silenced the expression of the three NO synthases,
NOS1–3. Although siRNA-mediated downregulation
of NOS2 and 3 did not impact on erlotinib resistance
(not shown), NOS1 silencing sensitised PC9ER cells to
erlotinib (Figure 5b). Next, we quenched cellular NO in
erlotinib-resistant cells with the NO-trap carboxy-
PTIO and revealed that this partially re-sensitised
PC9ER cells to erlotinib (Figure 5c). Although these
data suggest a role for NO in erlotinib resistance, the
levels of changes observed as compared with those seen
earlier (Figures 2 and 3) suggest that changes in NO are
GSH metabolism and erlotinib resistance
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not solely responsible for resistance downstream of
decreased GSH levels.
EA administration re-sensitises EGFRm/T790M
tumours to erlotinib in mouse xenografts
The GST inhibitor EA restored GSH levels and
erlotinib sensitivity in EGFRm/T790M cells in vitro
(Figure 2). EA is still used as a diuretic in humans
for conditions including high blood pressure and
heart failure [34]. Hence, we hypothesised that
co-administration of physiologically relevant doses of
EA might improve the responsiveness of EGFRm/
T790M tumours to erlotinib in vivo. PC9 or PC9ER
cells were injected subcutaneously in nude mice and
tumours were left to grow to 100mm3. The animals
were then treated daily with erlotinib and EA alone or
in combination. Co-administration of the drugs greatly
inhibited tumour growth with 60% of the animals
showing tumour volumes ⩽ 300mm3 at 25 days,
whereas those treated with either drug alone showed
more extensive disease (Figure 6a). This was associated
with increased survival (Figure 6b) and intra-
tumoural GSH levels in combination-treated animals
(Figure 6c). EA did not have any effect on erlotinib
sensitivity of PC9 xenografts in agreement with the lack
of further added sensitisation to erlotinib obtained with
this inhibitor in vitro (Supplementary Figure S7E).
Thus, co-administration of EA is probably a viable
strategy for the management of erlotinib-resistant
cancers in humans.
Decreased GSH synthetic enzymes expression
characterises erlotinib-resistant patients
Finally, we assessed whether the decrease in
GSH-synthetising enzymes observed in EGFRm/
T790M cell lines in vitro also occurred in patients.
Figure 4 Expression of EGFRm/T790M decreases intracellular GSH levels and NRF2 activity. (a–d) HEK293 cells were
transfected with empty vector control (EV), activated L858R-EGFR or activated/resistant L858R/T790M EGFR-mutant
constructs. (a) Quantitative reverse transcription PCR for EGFR, (b) colorimetric assay for GSH levels and (c) cell fractionation
followed by SDS-PAGE/western blotting for the indicated proteins were done on stable cell lines. Detection of lamin and tubulin
was used as loading controls for nuclear and cytoplasmic fractions, respectively. (d–g) PC9ER cells transfected with an EGFR
T790M-speciﬁc or NT siRNAs were subjected to (d) treatment with erlotinib before crystal violet staining, (e) colorimetric assay for
intracellular GSH levels, (f) quantitative PCR for GSH metabolic enzymes or (g) SDS-PAGE/western blotting. All data
representative of ≥ 3 experiments. (a,b,d–f) Values are average of n = 4± s.e.m. Statistics: (a,b) analysis of variance, (d,e,f)
Student’s t-test, *P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001. See also Supplementary Figures S6 and S7.
Hongde Li et al.
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First, we performed quantitative PCR for GSS, GSR,
GCLC and GCLM in paired biopsy samples from two
patients before (EGFRm alone) and after acquiring
EGFRm/T790M-mediated erlotinib resistance. In both
cases, resistance was accompanied by a decrease in one
or both of the rate-limiting enzymes for GSH bio-
synthesis, GCLC and GSS (Figure 6d). Moreover, this
association was not limited to syngeneic samples, as
RNA-Seq of four pairs of unrelated patients’ biopsies
revealed lower expression of at least one of these
enzymes in T790M tumours as compared with
non-T790M samples (Figure 6e). Therefore, decreased
expression of GSH synthetic enzymes is probably
associated with T790M-mediated erlotinib resistance in
lung cancer patients.
Discussion
EGFR TKIs such as erlotinib offer therapeutic
beneﬁt to NSCLC patients harbouring EGFRm [1–3].
However, the rapid development of resistance due in
50% of cases to acquisition of the secondary T790M
EGFR mutation greatly limits the ability of these
agents to prolong patient survival [5–8]. Although
decreased afﬁnity of the EGFRm/T790M for erlotinib
was thought responsible and new irreversible inhibitors
may be promising in circumventing this, additional
mechanisms of resistance are likely to be present.
Indeed, EGFRm/T790M cells still demonstrate
signiﬁcant loss of sensitivity to an irreversible com-
pound (Supplementary Figure S1C). This suggested
that resistance to erlotinib in EGFRm/T790MNSCLC
cells is mediated through additional mechanisms.
Accumulating evidence suggests EGFR mutations
to drive alteration in metabolic signatures, however,
majority of them fail to demonstrate efﬁcacy of tar-
geting these molecules in clinical settings or in vivo
models [35–37]. To identify novel resistance pathways,
we performed 1H-NMR metabonomic analysis of two
independent NSCLC erlotinib-sensitive/resistant cell
line pairs (PC9/PC9ER and H3255/H1975 cell lines).
These were chosen according to the several criteria.
First, both resistant cell lines shared the same T790M
resistance mutation. Second, although PC9ER cells
were obtained through selecting PC9 cells with
erlotinib making these two lines relatively isogenic,
H3255 and H1975 cells are genetically unrelated.
Third, the primary EGFR-activating mutations in the
two cell line pairs were different (ΔE746-A750 for
PC9/PC9ER cells, L858R for H3255/H1975 cells).
These criteria maximised the opportunity for metabolic
changes shared by both cell line pairs to be solely
Figure 5 Changes in NO levels modulate erlotinib response. (a) NO levels in PC9 and PC9ER cells were compared by
ﬂuorescence-activated cell sorting (FACS) using DAF-FM. Left: FACS proﬁle; right: fold changes in geometric mean. (b) PC9ER
cells transfected with non-targeting (NT) or NOS1 siRNAs or (c) PC9 and PC9ER cells treated± an NO-trap were exposed to a
dose range of erlotinib. Cell survival was determined by crystal violet staining. Statistics: Student’s t-test, *P⩽ 0.05.
GSH metabolism and erlotinib resistance
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Figure 6 Systemic EA administration re-sensitises PC9ER mouse xenografts to erlotinib. Nude mice (n = 10/condition) were
injected subcutaneously with PC9ER cells and treatment started when tumours reached 100 mm3. (a) Tumour volume and (b)
animals survival were monitored for 27 days. (a) Data are average± s.e.m. (b) End-point events occur when tumour volumes
⩾ 300 mm3. Log-rank test, Pabo0.01, Pbco0.01. (c) Following the last treatment, intratumoral GSH levels were measured
ex vivo by colorimetric assay. Statistics: (a) analysis of variance, (c) Student’s t-test, *Po0.05; **Po0.01. GSH-synthesising
enzymes expression is decreased in EGFRm/T790M patient tumours. mRNA levels for the indicated enzymes were compared by
quantitative PCR in two patients before (pre-T790M) and after (post-T790M) the onset of T790M-mediated erlotinib resistance (d)
or by RNA-Seq in four pairs of unrelated patients with (Pt1-4) or without (Pt5-8) T790M (e). Data in T790M samples are
normalised to those in the corresponding non-T790M samples. (f) Model of changes occurring downstream of T790M EGFR.
Hongde Li et al.
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dependent on the T790M mutation. One of the most
striking differences highlighted by our analysis was a
decrease in GSH levels in erlotinib-resistant cells
(Figure 1). The GSH pathway has long been involved
in cancer drug resistance [27, 28]. However, this was
traditionally associated with increased GSH levels [25,
26]. Indeed, GSH covalently binds to some drug
molecules in a GST-dependent manner leading to their
cellular export and quenches reactive oxidative species
often requiring for these compounds to act
[27, 28]. Therefore, an association between decreased
GSH levels and EGFR TKI resistance was surprising
and warranted further investigation of its relevance to
erlotinib responses.
Our experiments demonstrated that inhibition of
GSH biosynthesis by either RNAi or small molecules
made erlotinib-sensitive cells resistant to the drug
(Figure 2d–i). Conversely, inhibition of GSH-
degradation re-sensitised resistant cells to erlotinib
(Figure 2d–f). Hence, changes in GSH levels alone can
modulate the response of NSCLC cells to this drug and
decreased GSH levels accounts for erlotinib resistance
in PC9ER and H1975 cells. Comparative analysis
revealed a transcriptional downregulation of GSH-
synthesising enzymes in T790M cells (Figure 2b)
due to the impairment of NRF2, a downstream med-
iator of EGFR responsible for transcription of these
enzymes (Figure 3a and b). This occurred via upregu-
lation of the NRF2 inhibitor KEAP1 and/or down-
regulation of PALB2 and SQSTM1, two proteins
involved NRF2 stabilisation. Indeed, siRNA-mediated
silencing of KEAP1 in T790M cells sensitised them to
erlotinib (Figure 3g and h), whereas that of SQSTM1
or NRF2 made sensitive cells resistant to this drug
(Figure 3c–f). Importantly, decreased NRF2 activity
and GSH levels in resistant cells were a direct con-
sequence of acquiring the T790M mutation as intro-
ducing EGFRm/T790M in HEK293 cells, rather
than EGFRm alone, reproduced the changes asso-
ciated with erlotinib resistance (Figure 4a–c). Con-
versely, silencing EGFRm/T790M in PC9ER cells
reverted the changes in GSH levels and metabolic
enzymes seen upon acquisition of resistance by PC9
cells (Figure 4d–g).
It is unclear by what mechanism(s) the T790M
mutation induces the observed transcriptional changes
as the higher kinase activity of EGFRm/T790M [9]
should further enhance NRF2 activity. However,
mutant EGFRs differ from their wild-type counter-
parts in their subcellular localisation [38], which
probably results in the EGFRm/T790M having
different signalling partners as EGFRm or wild-type
EGFR. Further research will be required to investigate
this possibility.
We next attempted to identify the mechanism by
which decreased GSH levels cause erlotinib resistance.
GSH is a major cellular antioxidant [39], and its
reduced expression could result in increased reactive
oxidative species. In addition, single-nucleotide poly-
morphisms in antioxidant genes have been demon-
strated to be associated with survival outcome in
patients receiving TKI therapy [40]. Although super-
oxide levels were unchanged, NO levels were raised in
PC9ER as compared with PC9 cells (Figure 5a) and
NOS1 silencing or NO quenching sensitised PC9ER
cells to erlotinib (Figure 5b and c). GSH is known to
neutralise NO and protect against protein nitrosylation
[41, 42]. It is worth noting that EGFR is a target of
S-nitrosylation [43], but the consequence of this on
erlotinib response is currently unknown. However,
although our data suggest that NO probably con-
tributes to erlotinib resistance, this does not fully
explain the effects of reduced GSH. Glutathionylation
has a role in disease state by modifying the function of
target proteins [44] and assessing changes to the glu-
tathionylation proﬁle may identify proteins involved in
EGFRm/T790M-mediated erlotinib resistance.
Regardless of the mechanism underlying erlotinib
resistance downstream of decreased GSH levels, we
showed that the GSH pathway could be manipulated
for therapeutic beneﬁt. Indeed, systemic administration
of clinically relevant doses of EA, a GST inhibitor [45],
increased the intra-tumoural GSH levels (Figure 6c)
and re-sensitised EGFRm/T790M tumours to erlotinib
in a cancer cell xenograft mice model (Figure 6a–c). As
EA is an orally available diuretic used in humans with
limited toxicity [34], our ﬁndings could rapidly trans-
late into clinical practice if this sensitisation also occurs
in humans. Moreover, EA has already been used
together with classical chemotherapeutics such as
alkylating agents to prevent their GST-mediated
cellular export [34], leading to improved clinical
outcome. Therefore, EA may help manage erlotinib
resistance in EGFRm-NSCLC patients and improve
response to follow-on chemotherapeutic regimen.
However, it is unclear whether decreased GSH levels
only occurs downstream of the EGFRm/T790M or if
this is a common feature of other erlotinib resistance
pathways such as c-Met ampliﬁcation. Answering this
before clinical exploitation of our ﬁndings will help
more accurate patient selection for EA/erlotinib
combined trials.
Finally, we show our ﬁndings to be clinically
relevant using EGFRm and EGFRm/T790M lung
GSH metabolism and erlotinib resistance
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cancer samples (Figure 6d and e). The reduced number
of samples analysed reﬂects the fact that repeated
biopsy in NSCLC following the onset of EGFR TKI
resistance is rare, although this practice is now
changing. Nevertheless, we demonstrate in both
syngenic and unrelated patient samples that mRNA
levels for GSH-synthesising enzymes are decreased
in T790M tumours. Hence, probing for
GSH-synthesising enzymes may help, in a recurrent
setting, to predict the response to combinatorial
therapies of erlotinib and GSH level increasing agents.
To sum up, we demonstrate that decreased intra-
cellular level of GSH could mediate T790M-driven
erlotinib resistance in NSCLC and highlight the
molecular events involved (Figure 6f). Therapeutic
strategies that increase intra-tumoural GSH levels may
revert erlotinib resistance in the clinic.
Materials and Methods
Materials
Mercaptosuccinic acid (used at 50 μM), buthionine
sulfoximine (used at 40 μM) and EA (used at 50 and 100 μM in
PC9 and H1975 cells, respectively) were purchased from Sigma
(St Louis, MO, USA), whereas EGFR Inhibitor 324674 was
from Santa Cruz (Dallas, TX, USA) and Merck (Kenilworth,
NJ, USA), respectively. Antibodies against GSTpi, GPX1, GSS,
GSR, GCLC, GSTpi, SQSTM1 and DPP3 were from Abcam
(Cambridge, UK); antibodies targeting NRF2 and KEAP1 were
from Santa Cruz and anti-PALB2 was from Novus (Abingdon,
UK). The speciﬁcity of all antibodies employed here was
assessed by disappearance of the respective signal following
selective targeting of the expression of the corresponding protein
by siRNA treatment. Quantitect primers targeting GSTpi,
GPX1, GPX1, GSS, GSR and GCLC were from Qiagen
(Valencia, CA, USA). All other primers were synthesised by
Sigma. SiRNAs were purchased from Dharmacon (Little
Chalfont, UK). Dihydroethidine was from Invitrogen
(Waltham, MA, USA) and DAF-FM from Sigma.
Cell culture
All cell lines were obtained from the CRUK cell line bank
where they were authenticated and mycoplasma status assessed
through regular testing in our lab. Cell lines were grown in
Roswell ParkMemorial Institute with 10% fetal bovine serum at
37 °C, 5% CO2.
Extraction of the intracellular metabolites
Intracellular metabolites were extracted as reported
previously [46, 47] with some modiﬁcations. In brief, 107 cells per
condition were trypsinised and washed thrice in ice-cold
phosphate-buffered saline before metabolite extraction. Cell
pellets were resuspended in 0.6 ml cold water/methanol (1:2) and
subjected to three freeze–thaw cycles before sonication in a wet
ice bath for 15 min (cycles: 1 min pulse followed by 1 min pause).
Samples were then centrifuged (3200 g/4 °C, 10 min) and
supernatants transferred into cold Eppendorfs. The remaining
pellets were extracted twice more by the same method.
Supernatants from the three subsequent extractions were
combined, centrifuged (12 000 g/4 °C, 10 min) and freeze-dried
following vacuum-driven methanol evaporation. Lyophilised
samples were stored at − 80 °C. Ten biological replicates were
used for each group of cells.
Cellular metabonomic analysis by 1H-NMR
Freeze-dried intracellular metabolites extracts were dissolved
in 600 μl phosphate buffer 0.1 M (pH 7.4, 99.9%D2O) containing
0.001% sodium 3-trimethylsilyl-1-[2,2,3,3-2H4] propionate as
previously described [48]. All samples were centrifuged
(12 000 g/4 °C, 10 min) after short vortexing and supernatants
transferred into the 5 mm NMR tubes for NMR detection. All
one-dimensional 1H-NMR spectra were acquired on a Bruker
AVIII 600MHz NMR spectrometer equipped with a cryogenic
probe (BrukerBiospin, Rheinstetten, Germany) at 298 K. The
ﬁrst increment of NOESY pulse sequence was employed with
continuous wave irradiation on the water peak during recycle
delay and mixing time for water suppression. Recycle delay of
2 s and mixing time of 100 ms were set. The 90° pulse was
adjusted to 10 μs approximately and 64 scans were collected into
32 k data points with the spectral width of 20 p.p.m. For
metabolite assignments, two-dimensional NMR spectra
including 1H–1H COSY, 1H–1H TOCSY, 1H J-resolved, 1H–13C
HSQC and 1H–13C HMBC for typical samples were acquired
and processed as described previously [49].
NMR data analysis
The spectral region at δ 0.5–9.5 was integrated into bins
with the width of 0.002 p.p.m. (1.2 Hz) using AMIX package
(v3.8, BrukerBiospin). The range (δ 4.7–5.2) was removed to
eliminate the effects of water peak suppression. Each bin area
was normalised to the total area of the respective spectrum.
Multivariate data analysis was performed with the software
SIMCA-P+ (v 12.0, Umetrics, Umea, Sweden). The model was
built using the orthogonal projection to latent structure-
discriminant analysis (OPLS-DA) [50] with Pareto variance
(Par) scaling and sevenfold cross-validation. The parameter R2X
was the variation of X explained by the model and Q2 repre-
sented the predictability of the model. The validation of all the
models was further ensured by CV-analysis of variance
(Po0.05) [51]. To assist the biological interpretation of the
loadings generated from the models, the loadings was ﬁrstly
back-transformed [52] and then plotted with colour-coded
OPLS-DA coefﬁcients in MATLAB 7.1 using an in-house
script [53]. The colour code corresponded to the absolute
value of the OPLS-DA coefﬁcients (|r|), indicating the con-
tribution of each variable to explain the intergroup differentia-
tion. The value of |r|, 40.602, was considered to be signiﬁcant
(n = 10, Po0.05).
GSH colorimetric assay
A GSH colorimetric assay kit was purchased from BioAssay
Systems (Hayward, CA, USA) and used according to the
manufacturer’s instructions.
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siRNA transfection
A total of 1 × 104 PC9, PC9ER or H1975 cells per well in
six-well plates were transfected with siRNAs at 25 nM
(Dharmacon) for 24 h using RNAiMax (Invitrogen) following
the manufacturer’s protocol. Each protein was targeted with a
mix of four sequences. A total of 4 × 103 cells were re-seeded and
then incubated at 37 °C/5% CO2 for 24 h for target silencing
before further experiment steps.
Cell survival assay
For EA, buthionine sulfoximine and mercaptosuccinic acid,
cells were pretreated for 4 h before erlotinib addition (100 nM)
for 48 h. Cells were then ﬁxed and stained for 20 min with a 25%
methanol/0.5% crystal violet solution. Plates were washed in
running water, air-dried and the stain dissolved in 10% acetic
acid on a shaker before absorbance at 595 nm.
Quantitative PCR
Total cellular mRNA was extracted using the RNeasy kit
(Qiagen) and converted to complementary DNA with a
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Waltham, MA, USA). mRNA levels were quanti-
ﬁed using a Fast SYBRGreenMasterMix (Applied Biosystems)
on a 7900HT Fast Real time PCR System (Applied Biosystems).
qBase software (San Francisco, CA, USA) was used for data
analysis using TATA-binding protein and β-actin as internal
controls. The primers used were listed below (F, forward; R,
reverse): GCLm: (F): 5′-GGCACAGGTAAAACCAAATA
GTAAC-3′, (R): 5′-CAAATTGTTTAGCAAATGCAGTCA
-3′; GPX2: (F): 5′-TAAGTGGGCTCAGGCCTCTCT-3′, (R):
5′-GGTCATAGAAGGACTTGGCAATG-3′; GPX3: (F):
5′-GACAAGAGAAGTCGAAGATG-3′, (R): 5′-CTTCCTG
TAGTGCATTCAGTT-3′; GSTz1: (F): 5′-TCCTATTTCCG
AAGCTCCTGC-3′, (R): 5′-TTCAGTGCCTGGAAGTCCTT
AG-3′; GSTm1: (F): 5′-CTATGATGTCCTTGACCTCCA
CCGTATA-3′, (R): 5′-ATGTTCACGAAGGATAGTGGG
TAGCTGA-3′; Beta-Actin: (F): 5′-TCCTCCTGAGCGCAA
GTACTC-3′, (R): 5′-CTGCTTGCTGATCCACATCTG-3′;
KEAP1: (F): 5′-CAGATTGGCTGTGTGGAGTT-3′, (R):
5′-GCTGTTCGCAGTCGTACTTG-3′; SQSTM1: (F):
5′-CTGGGACTGAGAAGGCTCAC-3′, (R): 5′-GCAGCTG
ATGGTTTGGAAAT-3′; TBP: (F): 5′-TGCACAGGAGCCA
AGAGTGAA-3′, (R): 5′-CACATCACAGCTCCCCACCA-3′;
NRF2 primers: (F): 5′-GAGAGCCCAGTCTTCATTGC-3′,
(R): 5′-TGCTCAATGTCCTGTTGCAT-3′. Primers against the
other targets were purchased fromQiagen: GCLc (QT00037310),
GGT1 (QT00029470), GPX1 (QT00203392), GSTp1
(QT00086401), GSS (QT00014413) and GSR (QT00038325).
Tissue mRNA extraction and quantitative PCR
The origin of tissues and techniques used are as previously
reported [54]. In short, samples were obtained from EGFR-
mutant lung adenocarcinoma patients with acquired erlotinib
resistance under Human Investigations Protocol #111000928
(Yale Cancer Center, New Haven, CT). Those were reviewed by
a pathologist to ensure adequate tumour content. Tumour areas
were circled and microdissection performed to enrich for tumour
content.
Tissue mRNA extraction and RNA-Seq
The Illumina TruSeq RNA Sample Preparation Kit (Illu-
mina Cambridge Ltd, Essex, UK) was used for RNA tissue
extraction and analysis done as previously described [55].
Western blotting
Cells were lysed using 0.5% Triton X-100, 150 mM NaCl,
2 mM EDTA, 10% glycerol supplemented with protease
inhibitors cocktail tablets (Roche Diagnostics, Indianapolis, IN,
USA), 10 mM β-glycerophosphate, 1 mM Na3VO4 and 10 mM
NaF. Equal protein amounts were analysed by SDS-PAGE/
western blotting using the antibodies indicated.
Flow cytometry analysis of oxidative species
Cells (15 × 104/well in a six-well plate) were treated with
10 μM DAF-FM or dihydroethidine for 30 min, washed with
phosphate-buffered saline, trypsinised, pelleted and resuspended
in 1 ml of phosphate-buffered saline before ﬂow cytometry
using a BD FACSCalibur (DB Biosciences, Oxford, UK). The
geometric mean intensity was determined using FlowJo (Tree
Star Inc, Ashland, OR, USA).
Animal experiments
A total of 5x106 PC9ER or PC9 cells were injected
subcutaneously into the ﬂank of female BALB/c nude mice and
the tumours grew until they reached 100 mm3. Mice were then
randomized into three groups (n = 10) and treated by intraper-
itoneal injection of 25 mg kg− 1 per day erlotinib/0.5% w/v
methylcellulose and/or 6 mg kg− 1 per day EA/1% Tween 80 in
distilled water. Such treatments were administered daily from
day 7 to 26. Tumours were measured by caliper and volumes
calculated as V = 1/2*L*W2 (L; length, W; width of tumour).
Data analysis was performed by an investigator blinded to the
experimental conditions. All experiments complied with ethical
regulations as enforced by the local committee.
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